Omicron News and Research

RSS

Multicenter study determines the efficacy of SARS-CoV-2 vaccination against Post-Acute Sequelae of COVID-19

A new study published in Open Forum Infectious Diseases has focused on analyzing the efficacy of COVID-19 vaccination against PASC, utilizing multicentre data across the USA.

13 May 2022

Study explores macromolecular viral entry inhibitors as broad-spectrum first-line antivirals with anti-SARS-CoV-2 activities

Researchers created polystyrene sulfonate with significantly different molar masses, constructed these polymers as an exterior around spherical gold nanoparticles of various sizes to improve multivalency effects, measured antiviral effects of the antivirals on numerous viruses in vitro, and investigated the method of interaction of the leads with SARS-CoV-2 and lentiviral particles.

13 May 2022

Investigating effectiveness of mRNA booster against SARS-CoV-2 Omicron in individuals primed with mRNA or inactivated virus vaccines

Scientists have determined the effectiveness of different vaccination regimens in eliciting humoral immune responses against the SARS-CoV-2 Omicron variant.

13 May 2022

Exploring short-term effectiveness of COVID-19 booster vaccine and stable CD8+ T cell memory after three doses

A new study has longitudinally traced and profiled the CD8+ T cell responses after COVID-19 mRNA booster vaccination.

13 May 2022

Development of a novel surface plasmon resonance-based assay to determine kinetics of SARS-CoV-2 spike – human ACE2 interaction

A team of scientists has recently studied the kinetic and thermodynamic characteristics of interaction between human ACE2 and spike receptor-binding domains of different variants of SARS-CoV-2.

13 May 2022

SARS-CoV-2 N-terminal domain modulates S1/S2 cleavage and spike-mediated functions

In a recent study posted to the bioRxiv* preprint server, researchers explored the role of the N-terminal domain (NTD) of the severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) spike (S) protein in SARS-CoV-2 fusion with the host membranes and coronavirus disease 2019 (COVID-19).

12 May 2022

Bayesian viral allele selection for SARS-CoV-2 genomic surveillance

In a recent study posted to the bioRxiv* preprint server, researchers assessed the selection effects in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) using Bayesian viral allele selection.

12 May 2022

Cost-effective ovine antibody-based therapy against SARS-CoV-2 infection

A recent study published in the journal Antiviral Research explored alternative sources of polyclonal antibodies against SARS-CoV-2, which would be more cost-effective, amendable to regulatory approval, and widespread use.

12 May 2022

COVID-19 booster vaccination strategy found to be highly cost-effective in Australia

Researchers evaluated the cost-effectiveness of Australia’s COVID-19 booster vaccination strategy.

12 May 2022

Study projects the COVID-19 burden caused by Omicron infections in mainland China should the zero-COVID policy be lifted

A new paper describes a new epidemiological model of SARS-CoV-2 transmission that includes the burden of COVID-19, vaccination coverage, available antiviral therapies, and non-pharmaceutical interventions.

12 May 2022

Delta- and Omicron BA.1-variant specificity of B cell repertoires established by an initial Wuhan strain infection

Researchers performed an unbiased evaluation of the early memory B cell repertoire specific for the Omicron and Delta variants of SARS-CoV-2.

12 May 2022

Imprinted antibody responses towards SARS-CoV-2 Omicron subvariants

A new study analyzed the imprinted antibody responses towards the SARS-CoV-2 Omicron subvariants.

12 May 2022

Study estimates effectiveness of 2-dose and 3-dose mRNA vaccination against Omicron

In a recent study posted to the medRxiv* preprint server, researchers estimated the efficacy of two-dose and three-dose regimens of two messenger ribonucleic acid (mRNA) vaccines: Moderna’s mRNA-1273 and Pfizer-BioNTech’s BNT162b2 against coronavirus disease 2019 (COVID-19) caused due to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant.

12 May 2022

SARS-CoV-2 Omicron escapes immune response due to high ACE2 affinity and low antibody specificity

In a recent study published in the journal Vaccines, researchers revealed how severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) Omicron evades neutralizing antibodies (nAbs).

12 May 2022

Antifungal agent Bifonazole as an antiviral against SARS-CoV-2

In a recent study published in the journal Molecular Therapy, researchers identified Bifonazole, an imidazole-based antifungal agent, to have potent activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) using high-throughput screening of small molecules.

12 May 2022

Omicron News and Research

Multicenter study determines the efficacy of SARS-CoV-2 vaccination against Post-Acute Sequelae of COVID-19

Study explores macromolecular viral entry inhibitors as broad-spectrum first-line antivirals with anti-SARS-CoV-2 activities

Investigating effectiveness of mRNA booster against SARS-CoV-2 Omicron in individuals primed with mRNA or inactivated virus vaccines

Exploring short-term effectiveness of COVID-19 booster vaccine and stable CD8+ T cell memory after three doses

Development of a novel surface plasmon resonance-based assay to determine kinetics of SARS-CoV-2 spike – human ACE2 interaction

SARS-CoV-2 N-terminal domain modulates S1/S2 cleavage and spike-mediated functions

Bayesian viral allele selection for SARS-CoV-2 genomic surveillance

Cost-effective ovine antibody-based therapy against SARS-CoV-2 infection

COVID-19 booster vaccination strategy found to be highly cost-effective in Australia

Study projects the COVID-19 burden caused by Omicron infections in mainland China should the zero-COVID policy be lifted

Delta- and Omicron BA.1-variant specificity of B cell repertoires established by an initial Wuhan strain infection

Imprinted antibody responses towards SARS-CoV-2 Omicron subvariants

Study estimates effectiveness of 2-dose and 3-dose mRNA vaccination against Omicron

SARS-CoV-2 Omicron escapes immune response due to high ACE2 affinity and low antibody specificity

Antifungal agent Bifonazole as an antiviral against SARS-CoV-2

Unique binding property may explain the ability of delta variant to spread more rapidly

Effectiveness of COVID-19 monoclonal antibodies against SARS-CoV-2 Omicron variant

Vaccine features that could induce durable humoral immune responses against SARS-CoV-2

Susceptibility of four SARS-CoV-2 Omicron sub-lineages to vaccines and monoclonal antibodies

Study investigates antibody-mediated response against different SARS-CoV-2 variants

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News